CN118806758A - 用于治疗以炎症为特征的皮肤病状的包括irak4抑制剂的局部组合物 - Google Patents

用于治疗以炎症为特征的皮肤病状的包括irak4抑制剂的局部组合物 Download PDF

Info

Publication number
CN118806758A
CN118806758A CN202410650258.XA CN202410650258A CN118806758A CN 118806758 A CN118806758 A CN 118806758A CN 202410650258 A CN202410650258 A CN 202410650258A CN 118806758 A CN118806758 A CN 118806758A
Authority
CN
China
Prior art keywords
group
optionally substituted
aromatic heterocyclic
methyl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202410650258.XA
Other languages
English (en)
Chinese (zh)
Inventor
杰米·L·哈登
汉斯·E·J·霍夫兰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dermira Inc
Original Assignee
Dermira Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dermira Inc filed Critical Dermira Inc
Publication of CN118806758A publication Critical patent/CN118806758A/zh
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/10Anti-acne agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
CN202410650258.XA 2019-11-05 2020-11-05 用于治疗以炎症为特征的皮肤病状的包括irak4抑制剂的局部组合物 Pending CN118806758A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201962931132P 2019-11-05 2019-11-05
US62/931,132 2019-11-05
US202063046143P 2020-06-30 2020-06-30
US63/046,143 2020-06-30
PCT/US2020/059200 WO2021092239A1 (en) 2019-11-05 2020-11-05 Topical compositions comprising irak4 inhibitors for use in treating dermatological conditions characterised by inflammation
CN202080087596.7A CN114929223A (zh) 2019-11-05 2020-11-05 用于治疗以炎症为特征的皮肤病状的包括irak4抑制剂的局部组合物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN202080087596.7A Division CN114929223A (zh) 2019-11-05 2020-11-05 用于治疗以炎症为特征的皮肤病状的包括irak4抑制剂的局部组合物

Publications (1)

Publication Number Publication Date
CN118806758A true CN118806758A (zh) 2024-10-22

Family

ID=73654894

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202080087596.7A Pending CN114929223A (zh) 2019-11-05 2020-11-05 用于治疗以炎症为特征的皮肤病状的包括irak4抑制剂的局部组合物
CN202410650258.XA Pending CN118806758A (zh) 2019-11-05 2020-11-05 用于治疗以炎症为特征的皮肤病状的包括irak4抑制剂的局部组合物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202080087596.7A Pending CN114929223A (zh) 2019-11-05 2020-11-05 用于治疗以炎症为特征的皮肤病状的包括irak4抑制剂的局部组合物

Country Status (9)

Country Link
US (1) US20230125380A1 (https=)
EP (1) EP4054573A1 (https=)
JP (1) JP2023500707A (https=)
CN (2) CN114929223A (https=)
AU (1) AU2020380921A1 (https=)
BR (1) BR112022008610A2 (https=)
CA (1) CA3159624A1 (https=)
IL (1) IL292689A (https=)
WO (1) WO2021092239A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021300110A1 (en) * 2020-06-30 2023-02-02 Dermira, Inc. IRAK4 inhibitors and topical uses thereof
CN116675780B (zh) * 2023-06-02 2024-07-09 东北农业大学 犬成纤维细胞生长因子21融合蛋白制备及其在治疗特应性皮炎中的用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015068856A1 (en) 2013-11-08 2015-05-14 Takeda Pharmaceutical Company Limited Pyrazole for the treatment autoimmune disorders
JP2018524372A (ja) * 2015-07-15 2018-08-30 アウリジーン ディスカバリー テクノロジーズ リミテッド Irak−4阻害剤としてのインダゾール及びアザインダゾール化合物
WO2017205762A1 (en) * 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
US11167043B2 (en) * 2017-12-20 2021-11-09 Translate Bio, Inc. Composition and methods for treatment of ornithine transcarbamylase deficiency
IL315310A (en) * 2017-12-26 2024-10-01 Kymera Therapeutics Inc Irak degraders and uses thereof
AU2021300110A1 (en) * 2020-06-30 2023-02-02 Dermira, Inc. IRAK4 inhibitors and topical uses thereof

Also Published As

Publication number Publication date
WO2021092239A1 (en) 2021-05-14
IL292689A (en) 2022-07-01
US20230125380A1 (en) 2023-04-27
BR112022008610A2 (pt) 2022-08-09
EP4054573A1 (en) 2022-09-14
JP2023500707A (ja) 2023-01-10
CA3159624A1 (en) 2021-05-14
AU2020380921A1 (en) 2022-05-26
CN114929223A (zh) 2022-08-19

Similar Documents

Publication Publication Date Title
Noji et al. Discovery of a Janus kinase inhibitor bearing a highly three-dimensional spiro scaffold: JTE-052 (delgocitinib) as a new dermatological agent to treat inflammatory skin disorders
KR102123365B1 (ko) 항박테리아 치료제 및 예방제
KR101332585B1 (ko) 이미다조[1,2―a]피라진 유도체와, 신경계, 정신과 및 대사 장애 및 질환을 예방 또는 치료하기 위한 그의 용도
CN118974044A (zh) 化合物
CN107531696B (zh) 作为nmda受体调节剂的吡啶并嘧啶酮类及它们的用途
RU2667058C2 (ru) Ингибиторы фермента фосфодиэстеразы 10
CN118806758A (zh) 用于治疗以炎症为特征的皮肤病状的包括irak4抑制剂的局部组合物
JP7593956B2 (ja) Rhoキナーゼ阻害薬及び組成物並びにそれらの使用の方法
US20040058914A1 (en) Combination drugs
JP7813733B2 (ja) Irak4阻害剤及びそれらの局所的使用方法
EP3230286B1 (en) 1,2,4-triazolo[4,3-a]pyridine compounds and their use as positive allosteric modulators of mglur2 receptors
CN114929335A (zh) RORγt抑制剂及其局部用途
US12139505B2 (en) Compositions useful in therapy of autophagy-related pathologies, and methods of making and using the same
CN103827100A (zh) 用于降低血清尿酸的[1,2,4]噻二嗪1,1-二氧化物化合物
CN113164487B (zh) 磷酸二酯酶抑制剂
JP2026508302A (ja) ヒドロキシアルキルおよびメトキシアルキルトリプタミン
EP3322422A1 (en) Heteroaryl carbonitriles for the treatment of disease
WO2015162076A2 (en) Mglu2/3 antagonists for the treatment of intellectual disabilities
HK1227395A1 (en) Mglu2/3 antagonists for the treatment of intellectual disabilities

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination